| Abstrakt: |
Introduction: Interferon beta-1α, one of the drugs recommended by the World Health Organization in the COVID19 treatment protocol in early 2020, has been used to manage symptoms in patients with multiple sclerosis (MS). In these patients, TYK2 rs2304256, HLA-DQA1 rs9272105, and rs1448673 polymorphisms have been associated with treatment response to interferon. The present study evaluates the association of the above polymorphisms and therapeutic response to interferon beta 1-alpha in Kurdish patients affected by COVID-19. Methods and Materials: 124 mild COVID-19 patients participated in this study. ReciGen® (44 mcg/vial) (CinnaGen Company, Iran) was injected every other day. For this study, individuals with a score between 0-4 before treatment were considered having mild symptoms and were included. Symptom severity was assessed using the WHO scoring system, and the effectiveness of treatment was measured by subtracting the post-treatment score from the pretreatment score. A difference of < 0 was considered a responder (n = 74), whereas a difference of ≥ 0 was defined as a non-responder (n = 50). Subsequently, the genotype of rs2304256 and rs9272105 was determined using the PCRRFLP method. The rs1448673 polymorphism was also genotyped using the Tetra primer ARMS-PCR. Results: The rs9272105 AG genotype decreased response to RecigGen (codominant model, OR = 0.37, 95% CI 0.15-0.89, P = 0.027; overdominant model, OR = 0.33, 95% CI 0.14-0.79, P = 0.011). After stratification by sex, male rs2304256 CC and AA patients responded less to treatment in the overdominant model (OR = 0.16, 95% CI 0.04 - 0.55, P = 0.0094). Also, in the dominant model, male rs2304256 CC patients responded poorly (OR = 0.14, 95% CI 0.04 - 0.51, P = 0.0071), and females with rs2304256 AC and AA genotypes were less responsive (OR = 0.24, 95% CI 0.07 - 0.76, P = 0.0071). Conclusions: The rs2304256 and rs9272105 polymorphisms could be effective in response to IFN β-1a treatment in COVID-19 patients. [ABSTRACT FROM AUTHOR] |
